Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- Trial result Spotlight
Chronic lymphocytic leukemia
Sonrotoclax (BCL2 inhibitor) + zanubrutinib (BTK inhibitor) drives 99% PB uMRD4 and 100% 30-mo PFS in 1L CLL/SLL
Sonrotoclax (BGB-11417) is a next-generation oral BCL2 inhibitor combined with the oral BTK inhibitor zanubrutinib in the Phase 1/1b BGB-11417-101 study (NCT04277637) in treatment-naive CLL/SLL (sonro 320 mg cohort;…
NCT04277637 - Trial result Spotlight
Liver and bile duct cancer
Nivolumab+Ipilimumab (PD-1+CTLA-4) Sustains OS Benefit in 1L Unresectable HCC; Deep Responses Track With Long Survival
Nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) was tested vs lenvatinib/sorafenib (TKI SOC options) in the Phase 3 CheckMate-9DW first-line unresectable HCC trial (NCT04039607; n=668), with nivolumab…
NCT04039607 - Trial result Spotlight
Uterine (endometrial) cancer
Puxitatug Samrotecan B7-H4 ADC Posts 48% ORR in Relapsed Endometrial Cancer
Puxitatug samrotecan (AZD8205) is a B7-H4–directed topoisomerase I ADC tested in the Phase 1/2a BLUESTAR expansion (NCT05123482) in B7-H4-positive relapsed/metastatic endometrial or ovarian cancer after…
NCT05123482 - Trial result Spotlight
Skin cancer (non-melanoma)
Cemiplimab (PD-1) + response-adapted definitive RT delivers 86% 18-mo EFS in unresectable LA cSCC (RAMPART)
Cemiplimab-rwlc is an anti–PD-1 monoclonal antibody; in RAMPART (Phase II, multicenter, single-arm; NCT05574101), it was given neoadjuvantly (2 doses then response-adapted), concurrently with definitive radiotherapy…
NCT05574101 - Trial result Spotlight
Lymphoma
Golcadomide (CC-99282) CELMoD + rituximab drives 97% ORR/78% CR in heavily pretreated R/R follicular lymphoma
Golcadomide (GOLCA; CC-99282) is an oral cereblon E3 ligase modulator (CELMoD) that degrades Ikaros/Aiolos to combine direct tumor cell killing with immunomodulatory effects; in the Phase 1/2 CC-99282-NHL-001 study…
NCT03930953 - Trial result Spotlight
Pancreatic cancer
Atebimetinib (MEK deep cyclic inhibitor) + mGnP Delivers 42% ORR in 1L Metastatic PDAC
Atebimetinib is an oral next-generation MEK “deep cyclic inhibitor” (DCI) designed for pulsatile MAPK-pathway inhibition, and was combined with modified gemcitabine/nab-paclitaxel (mGnP; every-other-week dosing) in a…
NCT05585320 - Trial result Spotlight
Pancreatic cancer
Nesuparib (JPI-547) dual TNKS/PARP inhibitor + GemAbraxane hits 53.8% ORR in 1L advanced PDAC, but mFOLFIRINOX combo not tolerated
Nesuparib is an oral dual tankyrase (TNKS) and PARP inhibitor designed to induce “BRCAness” (via WNT/Hippo pathway modulation) and was combined with first-line GemAbraxane or modified FOLFIRINOX in a multicenter,…
NCT05257993 - Trial result Spotlight
Pancreatic cancer
Surufatinib (VEGFR/FGFR1/CSF1R TKI) + KN046 (PD-L1/CTLA-4 bispecific) + gem/nab-paclitaxel drives 71% ORR and 18.0-mo mOS in 1L advanced PDAC
Surufatinib is an oral multi-kinase inhibitor (VEGFR/FGFR1/CSF1R) with anti-angiogenic and macrophage-modulating activity, and KN046 is an IV PD-L1/CTLA-4 bispecific antibody designed to deliver dual checkpoint…
NCT05832892 - Trial result Spotlight
Small cell lung cancer
ABBV-706 (SEZ6-targeted topo-1 ADC) posts 52% ORR and 11.3-mo OS in R/R SCLC; combo with budigalimab looks feasible
ABBV-706 is a seizure-related 6 homolog (SEZ6)-targeting antibody–drug conjugate delivering a topoisomerase-1 inhibitor payload; this Phase 1 study (NCT05599984) tested ABBV-706 Q3W as monotherapy (N=124; 65% had ≥2…
NCT05599984 - Trial result Spotlight
Thyroid cancer
Pralsetinib (selective RET inhibitor) drives 92% ORR in pretreated RET fusion+ thyroid cancer; 68% ORR in RET-altered MTC
Pralsetinib is an oral, potent, selective RET tyrosine kinase inhibitor evaluated in the Phase 1/2 ARROW study (NCT03037385) in advanced/metastatic RET-altered thyroid cancer and medullary thyroid cancer (MTC). At…
NCT03037385 - Trial result Spotlight
Bladder and urothelial cancer
Ave + SG (TROP2 ADC) extends PFS across visceral/liver/bone subgroups vs avelumab alone in 1L maintenance aUC
Avelumab is a PD-L1 inhibitor, and sacituzumab govitecan (SG) is a TROP2-directed ADC delivering SN-38; this randomized Phase 2 JAVELIN Bladder Medley trial (NCT05327530) tested Ave + SG vs avelumab monotherapy as 1L…
NCT05327530 - Trial result Spotlight
Colorectal cancer
Ivonescimab (PD-1×VEGF bispecific) + mFOLFOX6 posts 70.8% ORR and 100% DCR in 1L unresectable mCRC (Phase 2)
Ivonescimab is an investigational tetrameric bispecific antibody co-targeting PD-1 and VEGF, here combined with oxaliplatin/5-FU/leucovorin (mFOLFOX6) as first-line therapy in a multiregional Phase 2 trial…
NCT05382442 - Trial result Spotlight
Colorectal cancer
Zongertinib (selective irreversible HER2 TKI) drives 45% ORR with mostly grade 1 diarrhea in HER2+ CRC
Zongertinib is an irreversible, HER2-selective tyrosine kinase inhibitor designed to spare wild-type EGFR (aiming to reduce classic EGFR-TKI rash/diarrhea) and was evaluated as monotherapy in a pooled subgroup of…
NCT04886804 - Trial result Spotlight
Multiple solid tumors
Olverembatinib (HQP1351) hits p38–CD36 lipid-scavenging axis, delivers 23% PR and 25.7-mo PFS in SDH-deficient GIST
Olverembatinib (HQP1351) is an oral multikinase TKI with p38 inhibition implicated here in downregulating CD36 (fatty-acid uptake), a metabolic vulnerability in SDH-deficient tumors. In the HQP1351SJ0003 Phase 1b…
NCT03594422 - Trial result Spotlight
Multiple solid tumors
NT-175 (TP53 R175H–HLA-A*02:01 eTCR; TGFβR2-knockout) drives 47.6% ORR across refractory solid tumors (83% PR in PDAC)
NT-175 is an autologous CRISPR/Cas9-edited engineered TCR T-cell therapy targeting the TP53 R175H neoantigen in an HLA-A*02:01-restricted manner, with endogenous TGFβR2 deleted (to reduce TGF-β–mediated suppression)…
NCT05877599 - Trial result Spotlight
Multiple solid tumors
HCB101 (SIRPα–IgG4 Fc; CD47 checkpoint blocker) shows early monotherapy PRs and high combo disease control in gastric cancer
HCB101 is a CD47–SIRPα axis inhibitor (engineered SIRPα–IgG4 Fc fusion) designed to preserve pro-phagocytic macrophage activity while minimizing red-blood-cell binding/hematologic toxicity. In the first-in-human…
NCT05892718 - Trial result Spotlight
Multiple solid tumors
Darlifarnib (KO-2806) FTI (RHEB/mTORC1) + adagrasib drives 67% ORR in KRAS G12C NSCLC (Ph1 FIT-001)
Darlifarnib (KO-2806) is a next-generation farnesyl transferase inhibitor designed to block farnesylation-dependent RHEB signaling and dampen mTORC1 activity (a proposed resistance node to KRAS G12C inhibition); in…
NCT06026410 - Trial result Spotlight
Multiple solid tumors
SIM0505 (anti-CDH6 topo-I ADC) drives 37% PRs in heavily pretreated gynecologic tumors
SIM0505 is a first-in-class cadherin-6 (CDH6)–targeted antibody–drug conjugate delivering the novel topoisomerase I payload CPT116; it was evaluated in a global Phase I first-in-human dose-escalation study in…
NCT06792552 - Trial result Spotlight
Multiple solid tumors
TILScore-Guided TIL Therapy Produces 33% ORR in Checkpoint-Refractory Solid Tumors
TILScore is an in situ transcriptomic biomarker used to select a metastasis for autologous TIL harvest and “reactive-enriched” manufacturing before lymphodepletion, TIL infusion, and high-dose IL-2. In a…
NCT03935893 - New trial Spotlight
Prostate cancer
Phase 2 [177Lu]Lu-PSMA-617 radioligand (PSMA-targeted beta emitter) with intermittent ADT
Mayo Clinic is running a randomized Phase 2 study in low-volume metastatic hormone-sensitive prostate cancer (de novo or recurrent after prior local therapy) testing whether adding [177Lu]Lu-PSMA-617 (lutetium Lu 177…
NCT07650240 Exploratory - New trial Spotlight
Breast cancer
Phase 1 ITI-5000 saRNA vaccine targets HERV-K/CT83 tumor antigens (LAMP-1 enhanced)
This first-in-human, Phase 1, multicenter, open-label study (VITAL-TNBC) tests ITI-5000, a lipid-nanoparticle (LNP)–delivered self-amplifying RNA (saRNA) therapeutic vaccine from Immunomic Therapeutics in people with…
NCT07652242 First-in-human - New trial Spotlight
Uterine (endometrial) cancer
Phase 3 PF-08634404 PD-1×VEGF bispecific antibody plus chemo vs pembrolizumab in pMMR endometrial cancer
Pfizer’s Symbiotic-GYN-18 (NCT07578649) is a Phase 3, open-label, randomized study testing whether PF-08634404—an investigational PD-1 and VEGF–targeted bispecific antibody—combined with standard chemotherapy…
NCT07578649 Registrational - New trial Spotlight
Multiple solid tumors
Phase 1 CLSP-5282 KRAS G12V–HLA-A03:01 T-cell engager in solid tumors
This Phase 1 open-label, multicenter, dose-escalation and expansion trial (SENTINEL-101) evaluates CLSP-5282 in adults whose advanced/metastatic solid tumors harbor KRAS G12V and who are HLA-A03:01 positive.…
NCT07650357 First-in-human - Trial result Spotlight
Melanoma
Intismeran autogene + pembrolizumab sustains 5-year RFS/DMFS benefit in resected melanoma
Intismeran autogene, also known as V940 or mRNA-4157, is Moderna/Merck’s individualized neoantigen mRNA therapy encoding up to 34 patient-specific tumor neoantigens, designed to broaden tumor-specific T-cell…
NCT03897881 - Trial result Spotlight
Melanoma
Ipilimumab (CTLA-4) + nivolumab–relatlimab (PD-1/LAG-3) drives 69% MPR (63% pCR) in resectable stage III melanoma—at the cost of 26% G3 and 1 G5 myocarditis
Neoadjuvant INR combines low-dose ipilimumab (CTLA-4 blockade) with fixed-dose nivolumab–relatlimab (PD-1/LAG-3 blockade) to deepen pathologic responses while keeping treatment short. In this Phase II trial in…
NCT06295159 - Trial result Spotlight
Melanoma
Nivolumab + Relatlimab (PD-1/LAG-3) Adds 10% Absolute 5-Year OS in 1L Melanoma
Nivolumab is a PD-1 inhibitor and relatlimab is a LAG-3 inhibitor evaluated as a fixed-dose combination versus nivolumab alone in the randomized, double-blind Phase 3 RELATIVITY-047 first-line trial in…
NCT03470922 - Trial result Spotlight
Colorectal cancer
Ivonescimab (PD-1×VEGF bispecific) + mFOLFOX6 posts 70.8% ORR and 100% DCR in 1L unresectable mCRC (Phase 2)
Ivonescimab is an investigational tetrameric bispecific antibody co-targeting PD-1 and VEGF, here combined with oxaliplatin/5-FU/leucovorin (mFOLFOX6) as first-line therapy in a multiregional Phase 2 trial…
NCT05382442 - Trial result Spotlight
Colorectal cancer
Nivolumab + ipilimumab (PD-1 + CTLA-4) improves long-term treatment-free survival vs nivolumab in MSI-H/dMMR mCRC
Nivolumab + ipilimumab (NIVO + IPI), a dual immune checkpoint regimen targeting PD-1 and CTLA-4, was compared with nivolumab (PD-1) monotherapy in the Phase 3 CheckMate 8HW trial in metastatic colorectal cancer with…
NCT04008030 - Trial result Spotlight
Colorectal cancer
Tislelizumab (PD-1) neoadjuvant drives 78.6% pCR + ctDNA MRD clears fast in dMMR/MSI-H colon cancer
Tislelizumab is an anti–PD-1 monoclonal antibody engineered to minimize Fcγ receptor binding; here it was given as neoadjuvant monotherapy (200mg IV Q3W ×4, then up to 8+ cycles per MDT) with tumor-informed ctDNA MRD…
NCT06262581 - Trial result Spotlight
Colorectal cancer
Onvansertib (PLK1 inhibitor) + FOLFIRI/Bev lifts ORR to 72% and improves PFS signal in 1L RAS-mut mCRC
Onvansertib (Onv) is an oral, selective polo-like kinase 1 (PLK1) inhibitor combined here with standard doublet chemotherapy plus bevacizumab (FOLFIRI+Bev or FOLFOX+Bev) in the randomized Phase 2 CRDF-004 trial…
NCT06106308
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.